Announcements

Updates on campus events, policies, construction and more.

close  

Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.

close  


Visit the News Hub

MRI scans shows promise in predicting dementia

Brain changes evident in scans before memory, cognitive decline

by Tamara BhandariNovember 20, 2018

Getty Images

One day, MRI brain scans may help predict whether older people will develop dementia, new research suggests.

In a small study, MRI brain scans predicted with 89 percent accuracy who would go on to develop dementia within three years, according to research at Washington University School of Medicine in St. Louis and the University of California San Francisco.

The findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.

“Right now it’s hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,” said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University’s Mallinckrodt Institute of Radiology. “We showed that a single MRI scan can predict dementia on average 2.6 years before memory loss is clinically detectable, which could help doctors advise and care for their patients.”

Alzheimer’s disease is a progressive, irreversible brain disorder that destroys memory and thinking skills. The disease affects 5.5 million Americans, according to the National Institutes of Health (NIH).

Neurologists can get a ballpark estimate of a patient’s risk of Alzheimer’s dementia using the Mini-Mental State Examination questionnaire, or by testing for the high-risk form of the gene ApoE, which increases a person’s risk of Alzheimer’s by up to 12-fold. Both tests were about 70 to 80 percent accurate in this study. Other assessments, such as PET scans for plaques of Alzheimer’s proteins in the brain, are good at detecting early signs of Alzheimer’s disease, but available to few patients. PET scans cost thousands of dollars and require radioactive materials not found in a typical hospital.

MRI brain scans are widely available and give doctors a glimpse into what’s going on inside a person’s brain. Raji and colleagues at the School of Medicine including Tammie Benzinger, MD, PhD, a professor of radiology, Parinaz Massoumzadeh, PhD, and Adedamola Adedokun, as well as radiologist Pratik Mukherjee, MD, PhD, of the University of California San Francisco, analyzed MRI scans for physical signs of impending cognitive decline.

They used a technique called diffusion tensor imaging to assess the health of the brain’s white matter, which encompasses the cables that enable different parts of the brain to talk to one another.

“Diffusion tensor imaging is a way of measuring the movement of water molecules along white matter tracts,” Raji said. “If water molecules are not moving normally it suggests underlying damage to white tracts that can underlie problems with cognition.”

Using information from the Alzheimer’s Disease Neuroimaging Initiative – a multisite collaboration that pools data, funding and expertise to improve clinical trials for Alzheimer’s disease – Raji and colleagues identified 10 people whose cognitive skills declined over a two-year period and matched them by age and sex with 10 people whose thinking skills held steady. The average age of people in both groups was 73. Then, the researchers analyzed diffusion tensor MRI scans taken just before the two-year period for all 20 people.

The researchers found that people who went on to experience cognitive decline had significantly more signs of damage to their white matter. The researchers repeated their analysis in a separate sample of 61 people, using a more refined measure of white matter integrity. With this new analysis, they were able to predict cognitive decline with 89 percent accuracy when looking at the whole brain. When the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.

“We could tell that the individuals who went on to develop dementia have these differences on diffusion MRI, compared with scans of cognitively normal people whose memory and thinking skills remained intact,” Raji said. “What we need now, before we can bring it into the clinic, is to get more control subjects and develop computerized tools that can more reliably compare individual patients’ scans to a baseline normal standard. With that, doctors might soon be able to tell people whether they are likely to have Alzheimer’s develop in the next few years.”

Although there are no drugs available yet to prevent or delay the onset of Alzheimer’s disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said. People could make decisions on their financial and living arrangements while they are still in full control of their faculties.

Raji C, Wang MB, Moe E, Palacios EM, Mukherjee P. Tract based spatial statistics in persons who will develop Alzheimer’s dementia: A study from the Alzheimer’s Disease Neuroimaging Initiative. Radiological Society of North America meeting. Nov. 25, 2018.

This work was funded by the Boerger Research Fund for Alzheimer’s Disease and Neurocognitive Disorders from the Foundation of the American Society of Neuroradiology.

Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Tamara covers infectious diseases, molecular microbiology, neurology, neuroscience, surgery, the Institute for Informatics, the Division of Physician-Scientists and the MSTP program. She holds a double bachelor's degree in molecular biophysics & biochemistry and in sociology from Yale University, a master's in public health from the University of California, Berkeley, and a PhD in biomedical science from the University of California, San Diego. She joined WashU Medicine Marketing & Communications in 2016. She has received three Robert G. Fenley writing awards from the American Association of Medical Colleges: a bronze in 2020 for "Mind’s quality control center found in long-ignored brain area," a silver in 2022 for "Mice with hallucination-like behaviors reveal insight into psychotic illness," and a bronze in 2023 for "Race of people given Alzheimer’s blood tests may affect interpretation of results." Since January of 2024, Tamara has been writing under the name Tamara Schneider.